Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

Alon Blue Square Israel has issued bonds worth US$81 million
Consumer & Retail

Alon Blue Square Israel has issued bonds worth US$81 million

Alon Blue Square Israel Ltd. has completed a fundraising to refinance and develop the company.

Learn more
Westminster Homecare has been acquired by Care at Home
Healthcare

Westminster Homecare has been acquired by Care at Home

The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.

Learn more
RVC Medical IT has been acquired by NEXUS AG
Private Equity | Healthcare | TMT

RVC Medical IT has been acquired by NEXUS AG

Main Capital Partners B.V. has sold RVC Medical IT B.V. to NEXUS AG.

Learn more